Skip to main content

Table 1 Patient and disease characteristics

From: Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Parameter

All (N = 221)

n (%)

Age ≤ 25 years (N = 53)

n (%)

Age > 25 years

(N = 168)

n (%)

p-value

Gender

   

1.0

 Male

129 (58)

31 (58)

98 (58)

 

 Female

92 (42)

22 (42)

70 (42)

 

Histology (all)

   

0.05

 DLBCL

98 (44)

18 (34)

80 (48)

 

 T-NHLa

43 (19)

17 (32)

26 (16)

 

 PMBCL

41 (19)

13 (25)

28 (17)

 

 Low-grade B-Cell lymphoma

10 (5)

0 (0)

10 (6)

 

 Hepatosplenic gamma-delta T-cell lymphoma

7 (3)

2 (4)

5 (3)

 

 Burkitt lymphoma

8 (4)

3 (6)

5 (3)

 

 Primary CNS Lymphoma

4 (2)

0 (0)

4 (2)

 

 Plasmablastic lymphoma

3 (1)

0 (0)

3 (2)

 

 Lymphoblastic lymphomab

3 (1)

0 (0)

3 (2)

 

 Mantle Cell Lymphoma

2 (1)

0 (0)

2 (1)

 

 Waldenstrom’s macroglobulinemia / lymphoplasmacytic lymphoma

1 (0)

0 (0)

1 (1)

 

 Cutaneous T-cell lymphoma/Sezary

1 (0)

0 (0)

1 (1)

 

Histology (main aggressive NHL)

 DLBCL

98 (54)

18 (38)

80 (60)

0.02

 T-NHL

43 (24)

17 (35)

26 (19)

 

 PMBCL

41 (23)

13 (27)

28 (21)

 

Double or Triple Hit / Double Expressor statusc

   

0.07

 Positive

14 (14)

0 (0)

14 (18)

 

 Negative

84 (86)

18 (100)

66 (83)

 

No. treatment lines before ASCT

   

0.93

 1

42 (19)

9 (17)

33 (20)

 

 2

82 (37)

21 (40)

61 (36)

 

 3

69 (31)

19 (36)

50 (30)

 

 4

21 (10)

3 (6)

18 (11)

 

 5

7 (3)

1 (2)

6 (4)

 

Response prior to ASCT

   

0.71

 CR

131 (59)

36 (68

95 (57)

 

 PR

71 (32)

14 (26)

57 (34)

 

 SD

9 (4)

1 (2)

8 (5)

 

 PD

9 (4)

2 (4)

7 (4)

 

 Untreated

1 (0)

0 (0)

1 (1)

 

sIPI

   

0.55

 0/1

84 (82)

22 (88)

62 (81)

 

 2/3

18 (18)

3 (12)

15 (20)

 

Conditioning regimen

   

0.55

 BEAM ± rituximab

138 (62)

37 (69)

101 (60)

 

 GemBuMel—based

71 (32)

14 (26)

57 (34)

 

KPS/LPS prior to transplant

   

0.62

 100

63 (33)

15 (33)

48 (33)

 

 90

89 (46)

21 (46)

68 (47)

 

 80

32 (17)

8 (17)

24 (16)

 

 70

7 (4)

1 (2)

6 (4)

 

 60

1 (1)

1 (2)

0 (0)

 
  1. DLBCL diffuse large B-cell lymphoma, T-NHL T-cell non-hodgkin lymphoma, PMBCL primary mediastinal B-cell lymphoma, CNS central nervous system, ASCT autologous hematopoietic stem cell transplantation, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, sIPI secondary international prognostic index, BEAM BCNU, etoposide, cytarabine and melphalan, GemBuMel gemcitabine, busulfan and melphalan, KPS/LPS karnofsky/lansky performance scale
  2. aIncludes: Large cell anaplastic lymphoma, ALK positive, n = 24; Large cell anaplastic lymphoma, ALK negative, n = 1; Extranodal NK / T-cell lymphoma, nasal type, n = 3; Peripheral T-cell Lymphoma, n = 15
  3. bIncludes: T lymphoblastic lymphoma, n = 2; B lymphoblastic lymphoma, n = 1
  4. cConsidered positive if either of the following positive: double hit / triple hit / double expressor. Calculated for patients with DLBCL histology only
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us